CME Session
Hybrid Session
Tian Zhang, MD, MHS
University of Texas Southwestern Medical Center
Dallas, Texas, United States
Disclosure: Disclosure(s): Contract Research: Astellas/Medivation (Terminated, August 31, 2021); Bristol Meyers Squibb (Terminated, August 31, 2021); Eli Lilly (Terminated, August 31, 2021); Exelixis (Terminated, August 31, 2021); Janssen (Terminated, August 31, 2021); Merck (Terminated, August 31, 2021); Merrimack (Terminated, August 31, 2021); Mirati Therapeutics (Terminated, August 31, 2021); Novartis (Terminated, August 31, 2021); Omniseq (Terminated, August 31, 2021); Pfizer (Terminated, August 31, 2021); Regeneron (Terminated, August 31, 2021)
Non-CE Consulting: Aravive (Ongoing); Aveo (Ongoing); Bayer (Ongoing); Bristol Meyers Squibb (Ongoing); Calithera Biosciences (Ongoing); Dendreon (Ongoing); Eisai (Ongoing); Eli Lilly (Ongoing); Exelixis (Ongoing); Janssen (Ongoing); Merck (Ongoing); Pfizer (Ongoing); QED Therapeutics (Ongoing); Sanofi (Ongoing); SeaGen (Ongoing)
Non-CE Speakers Bureau: Genomic Health (Terminated, December 31, 2020); Sanofi (Terminated, December 31, 2020)
Ownership Interest: I own stocks of the Commercial entity: Nanorobotics (Ongoing)
Salary or Employment Relationship (does not included small non-employed consulting arrangements): Archimmune Therapeutics (Ongoing); Capio Biosciences (Ongoing)
spouse: Archimmune Therapeutics (Ongoing); Capio Biosciences (Ongoing)